Chemoresistance in human ovarian cancer: The role of apoptotic regulators

被引：143

作者：

Michael Fraser

Brendan Leung

Arezu Jahani-Asl

Xiaojuan Yan

Winston E Thompson

Benjamin K Tsang

机构：

[1] Dept. Obstet./Gynecol./Molec. Med., University of Ottawa, Ottawa Health Research Institute, Ottawa

[2] Dept. of Obstetrics and Gynecology, Cooperative Repro. Sci. Res. Center, Morehouse School of Medicine, Atlanta

来源：

Reproductive Biology and Endocrinology | / 1卷 / 1期

关键词：

Ovarian Cancer; Ovarian Cancer Cell; Human Ovarian Cancer Cell; Sporadic Breast Cancer; Death Effector Domain;

D O I：

10.1186/1477-7827-1-66

中图分类号：

学科分类号：

摘要：

Ovarian cancer is among the most lethal of all malignancies in women. While chemotherapy is the preferred treatment modality, chemoresistance severely limits treatment success. Recent evidence suggests that deregulation of key pro- and anti-apoptotic pathways is a key factor in the onset and maintenance of chemoresistance. Furthermore, the discovery of novel interactions between these pathways suggests that chemoresistance may be multi- factorial. Ultimately, the decision of the cancer cell to live or die in response to a chemotherapeutic agent is a consequence of the overall apoptotic capacity of that cell. In this review, we discuss the biochemical pathways believed to promote cell survival and how they modulate chemosensitivity. We then conclude with some new research directions by which the fundamental mechanisms of chemoresistance can be elucidated. © 2003 Frazer et al; licensee BioMed Central Ltd.

引用

页数：13

共 114 条

[21]

Ashkenazi A., Dixit V.M., Death receptors: Signaling and modulation, Science, 281, pp. 1305-1308, (1998)

[22]

Krammer P.H., CD95(APO-1/Fas)-mediated apoptosis: Live and let die, Adv. Immunol., 71, pp. 163-210, (1999)

[23]

Uslu R., Jewett A., Bonavida B., Sensitization of human ovarian tumor cells by subtoxic CDDP to anti-fas antibody-mediated cytotoxicity and apoptosis, Gynecol. Oncol., 62, pp. 282-291, (1996)

[24]

Rothe M., Wong S.C., Henzel W.J., Goeddel D.V., A novel family of putative signal transducers associated with the cytoplasmic domain of the 75 kDa tumor necrosis factor receptor, Cell, 78, pp. 681-692, (1994)

[25]

Kruppa G., Thoma B., Machleidt T., Wiegmann K., Kronke M., Inhibition of tumor necrosis factor (TNF)-mediated NF-kappa B activation by selective blockade of the human 55-kDa TNF receptor, J. Immunol., 148, pp. 3152-3157, (1992)

[26]

Irmler M., Thome M., Hahne M., Schneider P., Hofmann K., Steiner V., Bodmer J.L., Schroter M., Burns K., Mattmann C., Rimoldi D., French L.E., Tschopp J., Inhibition of death receptor signals by cellular FLIP, Nature, 388, pp. 190-195, (1997)

[27]

Thome M., Schneider P., Hofmann K., Fickenscher H., Meinl E., Neipel F., Mattmann C., Burns K., Bodmer J.L., Schroter M., Scaffidi C., Krammer P.H., Peter M.E., Tschopp J., Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors, Nature, 386, pp. 517-521, (1997)

[28]

Goltsev Y.V., Kovalenko A.V., Arnold E., Varfolomeev E.E., Brodianskii V.M., Wallach D., CASH a novel caspase homologue with death effector domains, J. Biol. Chem., 272, pp. 19641-19644, (1997)

[29]

Srinivasula S.M., Ahmad M., Lin J.H., Poyet J.L., Fernandes-Alnemri T., Tsichlis P.N., Alnemri E.S., CLAP a novel caspase recruitment domain- Containing protein in the tumor necrosis factor receptor pathway regulates NF-kappaB activation apoptosis, J. Biol. Chem., 274, pp. 17946-17954, (1999)

[30]

Xiao C.W., Yan X., Li Y., Reddy S.A., Tsang B.K., Resistance of human ovarian cancer cells to tumor necrosis factor alpha is a consequence of nuclear factor kappaB-mediated induction of Fas-associated death domain-like interleukin-1beta-converting enzyme-like inhibitory protein, Endocrinology, 144, pp. 623-630, (2003)

← 1 2 3 4 5 6 7 8 9 10 →